J. Filippi, P. Allen, and L. Peyrin-biroulet, Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review, Current Drug Targets, vol.12, issue.10, p.5, 2011.
DOI : 10.2174/138945011796818153

A. Gustavsson, J. Halfvarson, and G. Jarnerot, Long-Term Colectomy Rate After Intensive Intravenous Corticosteroid Therapy for Ulcerative Colitis Prior to the Immunosuppressive Treatment Era, The American Journal of Gastroenterology, vol.132, issue.1, pp.2513-2522, 2007.
DOI : 10.1053/j.gastro.2006.12.038

R. Cohen, R. Stein, and S. Hanauer, Intravenous cyclosporin in ulcerative colitis: a five-year experience, The American Journal of Gastroenterology, vol.91, issue.6, pp.1587-92, 1999.
DOI : 10.1056/NEJM199406303302601

C. Rayner, G. Mccormack, and M. Kamm, Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.117, issue.3, pp.303-311, 2003.
DOI : 10.1016/S0016-5085(99)70445-2

S. Campbell, S. Travis, and D. Jewell, Ciclosporin use in acute ulcerative colitis, European Journal of Gastroenterology & Hepatology, vol.17, issue.1, pp.79-84, 2005.
DOI : 10.1097/00042737-200501000-00016

D. Bojic, Z. Radojicic, D. Jewell, and S. Travis, Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992???1993 cohort, Inflammatory Bowel Diseases, vol.107, issue.6, pp.823-831, 2009.
DOI : 10.1111/j.1365-2036.2007.03300.x

J. Arts, D. Haens, G. Rutgeerts, and P. , Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis, Inflammatory Bowel Diseases, vol.47, issue.2, pp.73-81, 2004.
DOI : 10.1111/j.1572-0241.2000.02186.x

D. Moskovitz, G. Van-assche, and P. Rutgeerts, Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.760-765, 2006.
DOI : 10.1016/j.cgh.2006.04.001

W. Sandborn, P. Rutgeerts, and J. Colombel, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Oussalah A, Evesque L, Peyrin-Biroulet L. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization, Gastroenterology Am J Gastroenterol, vol.137105, issue.10, pp.1250-602617, 2009.

D. Turner, C. Walsh, and A. Griffiths, Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.103-113, 2007.
DOI : 10.1016/j.cgh.2006.09.033

S. Lichtiger, D. Present, and S. Hanauer, Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

C. Bello, J. Belaiche, and C. Reenaers, Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids, Journal of Crohn's and Colitis, vol.353, issue.23
DOI : 10.1056/NEJMoa050516

S. Ardizzone, A. Cassinotti, G. Porro, A. Oussalah, and M. Bigard, Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut, Clin Gastroenterol Hepatol, vol.960, issue.16, pp.483-489

S. Travis, E. Stange, and M. Gassull, European evidence-based Consensus on the management of ulcerative colitis: Current management, Journal of Crohn's and Colitis, vol.132, issue.Suppl 2, pp.24-62, 2008.
DOI : 10.1053/j.gastro.2006.11.015

G. Brisinda, S. Vanella, and M. G. , Surgical Prophylaxis of Pouchitis in Ulcerative Colitis, Digestive Diseases and Sciences, vol.67, issue.5
DOI : 10.1002/bjs.1800670802

D. Patton, N. Gupta, and M. Heyman, Postoperative Outcome of Colectomy for Pediatric Patients With Ulcerative Colitis, Journal of Pediatric Gastroenterology and Nutrition, vol.51, issue.2, pp.151-155
DOI : 10.1097/MPG.0b013e3181c99290

A. El-raouf, N. Hak, and M. El-hemaly, Outcome of pouch surgery for ulcerative colitis: single center experience, Hepatogastroenterology, vol.55, pp.2130-2134, 2008.

A. Waljee, P. Higgins, and A. Morris, Perceived and Actual Quality of Life With Ulcerative Colitis: A Comparison of Medically and Surgically Treated Patients, The American Journal of Gastroenterology, vol.68, issue.4, pp.794-803
DOI : 10.1097/00004836-200609000-00002

F. Edwards and S. Truelove, The course and prognosis of ulcerative colitis: Part I Short-term prognosis, Gut, vol.4, issue.4, pp.299-315, 1963.
DOI : 10.1136/gut.4.4.299

S. Truelove and L. Witts, Cortisone in Ulcerative Colitis, BMJ, vol.2, issue.4947, pp.1041-1049, 1955.
DOI : 10.1136/bmj.2.4947.1041

D. Hurlstone, D. Sanders, and M. Thomson, Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm?, Gut, vol.56, issue.6, pp.838-884, 2007.
DOI : 10.1136/gut.2006.106294

Y. Gonzalez-lama, I. Fernandez-blanco, and J. Gisbert, P028 OPEN-LABEL INFLIXIMAB THERAPY IN ULCERATIVE COLITIS: A MULTICENTER SURVEY OF RESULTS AND PREDICTORS OF RESPONSE, Journal of Crohn's and Colitis Supplements, vol.1, issue.1, pp.1609-1623, 2008.
DOI : 10.1016/S1873-9954(07)70040-X

C. Leijonmarck, P. Persson, and G. Hellers, Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study., Gut, vol.31, issue.3, pp.329-362, 1990.
DOI : 10.1136/gut.31.3.329

O. Bonnevie, V. Binder, and P. Riis, The prognosis of ulcerative colitis, Scand J Gastroenterol, vol.9, pp.81-91, 1974.

C. Hendriksen, S. Kreiner, and V. Binder, Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen., Gut, vol.26, issue.2, pp.158-63, 1985.
DOI : 10.1136/gut.26.2.158

K. Froslie, J. Jahnsen, and M. Vatn, Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort, Gastroenterology, vol.133, issue.2, pp.412-434, 2007.
DOI : 10.1053/j.gastro.2007.05.051

J. Colombel, P. Rutgeerts, and W. Sandborn, Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis, Gastroenterology, vol.141, issue.4
DOI : 10.1053/j.gastro.2011.06.054

C. Seow, A. Newman, and G. Greenberg, Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54
DOI : 10.1136/gut.2009.183095

M. Henriksen, J. Jahnsen, and B. Moum, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, vol.57, issue.11, pp.1518-1541, 2008.
DOI : 10.1136/gut.2007.146357

M. Ferrante, S. Vermeire, and P. Rutgeerts, Long-term outcome after infliximab for refractory ulcerative colitis, Journal of Crohn's and Colitis, vol.24, issue.9, pp.219-244, 2008.
DOI : 10.1111/j.1365-2036.2006.03064.x

URL : https://academic.oup.com/ecco-jcc/article-pdf/2/3/219/7799234/2-3-219.pdf

W. Cacheux, P. Seksik, and J. Cosnes, Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis, The American Journal of Gastroenterology, vol.132, issue.3, pp.637-679, 2008.
DOI : 10.1136/bmj.314.7077.363

URL : https://hal.archives-ouvertes.fr/hal-00815884

M. Manosa, E. Cabre, and E. Domenech, Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids, Inflamm Bowel Dis, p.21634, 1002.

S. Vermeire, G. Van-assche, and P. Rutgeerts, C-Reactive Protein as a Marker for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.52, issue.5, pp.661-666, 2004.
DOI : 10.1007/s11894-003-0040-8

B. Calkins, A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12
DOI : 10.1007/BF01536701

L. Beaugerie, N. Massot, and J. Cosnes, Impact of cessation of smoking on the course of ulcerative colitis, The American Journal of Gastroenterology, vol.42, issue.7, pp.2113-2119, 2001.
DOI : 10.1111/j.1572-0241.2001.03944.x

E. Boyko, D. Perera, and T. Inui, Effects of Cigarette Smoking on the Clinical Course of Ulcerative Colitis, Scandinavian Journal of Gastroenterology, vol.29, issue.9, pp.1147-52, 1988.
DOI : 10.1136/gut.29.3.352

W. Selby, S. Griffin, and M. Solomon, Appendectomy protects against the development of ulcerative colitis but does not affect its course, The American Journal of Gastroenterology, vol.28, issue.11, pp.2834-2842, 2002.
DOI : 10.1111/j.1572-0241.2000.01680.x

J. Hallas, D. Gaist, and H. Sorensen, Appendicectomy has no beneficial effect on admission rates in patients with ulcerative colitis, Gut, vol.53, issue.3, pp.351-355, 2004.
DOI : 10.1136/gut.2003.016915

J. Cosnes, F. Carbonnel, and J. Gendre, Effects of appendicectomy on the course of ulcerative colitis, Gut, vol.51, issue.6, pp.803-810, 2002.
DOI : 10.1136/gut.51.6.803

G. Radford-smith, J. Edwards, and T. Florin, Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease, Gut, vol.51, issue.6, pp.808-821, 2002.
DOI : 10.1136/gut.51.6.808

T. Florin, N. Pandeya, and G. Radford-smith, Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases, Gut, vol.53, issue.7, pp.973-982, 2004.
DOI : 10.1136/gut.2003.036483

G. Ho, H. Lee, and J. Satsangi, Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis, The American Journal of Gastroenterology, vol.55, issue.3, pp.673-681, 2009.
DOI : 10.1053/gast.2003.50197

G. Bowen, G. Irons, and J. Kirsner, Early experiences with azathioprine in ulcerative colitis; a note of caution, JAMA: The Journal of the American Medical Association, vol.195, issue.6, pp.460-464, 1966.
DOI : 10.1001/jama.195.6.460

D. Jewell and S. Truelove, Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial, BMJ, vol.4, issue.5945, pp.627-657, 1974.
DOI : 10.1136/bmj.4.5945.627

M. Campieri, G. Lanfranchi, D. Monte, and P. , Treatment of ulcerative colitis with highdose 5-aminosalicylic acid enemas, Lancet, vol.2, pp.270-271, 1981.

K. Schroeder, W. Tremaine, and D. Ilstrup, Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, New England Journal of Medicine, vol.317, issue.26, pp.1625-1634, 1987.
DOI : 10.1056/NEJM198712243172603

C. Probert, S. Hearing, and A. Forbes, Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial, Gut, vol.52, issue.7, pp.998-1002, 2003.
DOI : 10.1136/gut.52.7.998

J. Gornet, S. Couve, and M. Lemann, Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study, Alimentary Pharmacology and Therapeutics, vol.16, issue.2, pp.175-81, 2003.
DOI : 10.1016/S0002-9270(02)03987-4

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01686.x/pdf

T. Ochsenkuhn, M. Sackmann, and B. Goke, Infliximab for acute, not steroid-refractory ulcerative colitis, European Journal of Gastroenterology & Hepatology, vol.16, issue.11, pp.1167-71, 2004.
DOI : 10.1097/00042737-200411000-00014

P. Rutgeerts, W. Sandborn, and J. Colombel, Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005.
DOI : 10.1056/NEJMoa050516

W. Faubion, J. Loftus, E. , J. Sandborn, and W. , The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study, Gastroenterology, vol.121, issue.2, pp.255-60, 2001.
DOI : 10.1053/gast.2001.26279

M. Henriksen, J. Jahnsen, and B. Moum, Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study), Inflammatory Bowel Diseases, vol.49, issue.7, pp.543-50, 2006.
DOI : 10.1023/B:DDAS.0000020506.84248.f9

I. Solberg, I. Lygren, and B. Moum, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scandinavian Journal of Gastroenterology, vol.19, issue.2, pp.431-471, 2009.
DOI : 10.3109/00365529609004876

T. Jess, L. Riis, I. Vind, and P. Munkholm, Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark, Inflammatory Bowel Diseases, vol.55, issue.4, pp.481-490, 2007.
DOI : 10.1136/gut.2005.079350

G. Jarnerot, E. Hertervig, and B. Curman, Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study, Gastroenterology, vol.128, issue.7, pp.1805-1816, 2005.
DOI : 10.1053/j.gastro.2005.03.003

C. Lees, D. Heys, and I. Arnott, A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.354, issue.Suppl. A, pp.411-420, 2007.
DOI : 10.1155/2005/269076

B. Maldonado-perez, L. Castro-laria, J. Herrerã-as-gutierrez, D. Vitis, I. Guidi et al., P176 -Maintenance therapy with infliximab in corticosteroid-dependent patients with ulcerative colitis (preliminary results) Journal of Crohn " s and Colitis P031 -Mucosal healing and risk of colectomy in ulcerative colitis patients:S23. 62. Oussalah A -Evesque L, Peyrin-Biroulet L. -A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization, S80 Journal of Crohn " s and Colitis Am J Gastroenterol, vol.333105, issue.3, pp.23-32617, 2009.

J. Sl-fau-jewell, D. , J. D. Fau-travis, S. Travis, and S. , Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from, Aliment Pharmacol Ther, vol.25, pp.1055-60, 2000.

A. Kohn, M. Fau-daperno, and C. Prantera, Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up, Alimentary Pharmacology & Therapeutics, vol.240, issue.5, pp.747-56, 2007.
DOI : 10.1016/0016-5085(85)90201-X

A. Aratari, C. Papi, and R. Caprilli, Colectomy rate in acute severe ulcerative colitis in the infliximab era, Digestive and Liver Disease, vol.40, issue.10, pp.821-827, 2008.
DOI : 10.1016/j.dld.2008.03.014

L. Peyrin-biroulet, C. -laclotte, and M. Bigard, Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study, World Journal of Gastroenterology, vol.13, issue.16
DOI : 10.3748/wjg.v13.i16.2328

A. Oussalah, C. -laclotte, and L. Peyrin-biroulet, Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience, Alimentary Pharmacology & Therapeutics, vol.372, issue.Suppl. 1, pp.966-72, 2008.
DOI : 10.3748/wjg.v13.i16.2328

T. Ljung, P. -karlen, and R. Lofberg, Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County, Gut, vol.53, issue.6, pp.849-53, 2004.
DOI : 10.1136/gut.2003.018515

R. Ea-harris, A. Ghosh, and S. , Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England, Aliment Pharmacol Ther, vol.29, pp.308-322, 2009.

J. Lennard-jones, Classification of Inflammatory Bowel Disease, Scandinavian Journal of Gastroenterology, vol.284, issue.sup170, pp.2-6, 1989.
DOI : 10.1136/bmj.284.6309.91

M. Joffe and P. Rosenbaum, Invited Commentary: Propensity Scores, American Journal of Epidemiology, vol.150, issue.4, pp.327-360, 1999.
DOI : 10.1093/oxfordjournals.aje.a010011

J. Satsangi, M. Silverberg, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

A. Teisner, M. Ainsworth, and J. Brynskov, Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience, Scandinavian Journal of Gastroenterology, vol.2, issue.12
DOI : 10.1016/j.crohns.2008.03.004

L. Moore, K. Gaffney, and B. Shen, Comparison of the natural history of ulcerative colitis in African Americans and non-Hispanic Caucasians: A historical cohort study, Inflammatory Bowel Diseases, vol.9, issue.4, p.21796, 1002.
DOI : 10.1002/ibd.20298

C. Jf-sandborn, W. Rutgeerts, and P. , Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, vol.362, issue.15, pp.1383-95, 2010.

. Abbreviations, ACT: Active Ulcerative Colitis Trial; 5-ASA: 5-aminosalicylates; CI: confidence interval; HR: hazard ratio; IPAA: ileal pouch-anal canal anastomosis; IPDRA: ileal pouch distal rectal anastomosis; IQR: interquartile range; IBD: inflammatory bowel disease; ROC: receiver operating characteristic; TNF: tumor necrosis factor; UC: ulcerative colitis

J. Filippi, P. Allen, and X. Hebuterne, Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review, Current Drug Targets, vol.12, issue.10, 2011.
DOI : 10.2174/138945011796818153

A. Gustavsson, J. Halfvarson, and A. Magnuson, Long-Term Colectomy Rate After Intensive Intravenous Corticosteroid Therapy for Ulcerative Colitis Prior to the Immunosuppressive Treatment Era, The American Journal of Gastroenterology, vol.132, issue.1, pp.2513-2522, 2007.
DOI : 10.1053/j.gastro.2006.12.038

R. Cohen, R. Stein, and S. Hanauer, Intravenous cyclosporin in ulcerative colitis: a five-year experience, The American Journal of Gastroenterology, vol.91, issue.6, pp.1587-92, 1999.
DOI : 10.1056/NEJM199406303302601

C. Rayner, G. Mccormack, and A. Emmanuel, Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.117, issue.3, pp.303-311, 2003.
DOI : 10.1016/S0016-5085(99)70445-2

S. Campbell, S. Travis, and D. Jewell, Ciclosporin use in acute ulcerative colitis, European Journal of Gastroenterology & Hepatology, vol.17, issue.1, pp.79-84, 2005.
DOI : 10.1097/00042737-200501000-00016

D. Bojic, Z. Radojicic, and M. Nedeljkovic-protic, Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992???1993 cohort, Inflammatory Bowel Diseases, vol.107, issue.6, pp.823-831, 2009.
DOI : 10.1111/j.1365-2036.2007.03300.x

J. Arts, D. Haens, G. Zeegers, and M. , Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis, Inflammatory Bowel Diseases, vol.47, issue.2, pp.73-81, 2004.
DOI : 10.1111/j.1572-0241.2000.02186.x

D. Moskovitz, G. Van-assche, and B. Maenhout, Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.760-765, 2006.
DOI : 10.1016/j.cgh.2006.04.001

W. Sandborn, P. Rutgeerts, and B. Feagan, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization, Gastroenterology Am J Gastroenterol, vol.137105, issue.10, pp.1250-602617, 2009.

D. Turner, C. Walsh, and A. Steinhart, Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.103-113, 2007.
DOI : 10.1016/j.cgh.2006.09.033

S. Lichtiger, D. Present, and A. Kornbluth, Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

G. Van-assche, D. Haens, G. Noman, and M. , Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D???Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D???Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy., Gastroenterology, vol.125, issue.4, pp.1025-1056, 2003.
DOI : 10.1016/S0016-5085(03)01214-9

C. Bello, J. Belaiche, and E. Louis, Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids, Journal of Crohn's and Colitis, vol.353, issue.23, pp.196-202, 2011.
DOI : 10.1056/NEJMoa050516

S. Ardizzone, A. Cassinotti, and P. Duca, Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.9, issue.6, pp.483-492, 2011.
DOI : 10.1016/j.cgh.2010.12.028

L. Peyrin-biroulet, A. Oussalah, and N. Williet, Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease, Gut, vol.60, issue.7, pp.930-936, 2011.
DOI : 10.1136/gut.2010.227884

J. Lennard-jones, Classification of Inflammatory Bowel Disease, Scandinavian Journal of Gastroenterology, vol.284, issue.sup170, pp.2-6, 1989.
DOI : 10.1136/bmj.284.6309.91

M. Joffe and P. Rosenbaum, Invited Commentary: Propensity Scores, American Journal of Epidemiology, vol.150, issue.4, pp.327-360, 1999.
DOI : 10.1093/oxfordjournals.aje.a010011

J. Satsangi, M. Silverberg, and S. Vermeire, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

A. Teisner, M. Ainsworth, and J. Brynskov, Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience, Scandinavian Journal of Gastroenterology, vol.2, issue.12, pp.1457-63, 2010.
DOI : 10.1016/j.crohns.2008.03.004

M. Ferrante, S. Vermeire, and H. Fidder, Long-term outcome after infliximab for refractory ulcerative colitis, Journal of Crohn's and Colitis, vol.24, issue.9, pp.219-244, 2008.
DOI : 10.1111/j.1365-2036.2006.03064.x

L. Moore, K. Gaffney, and R. Lopez, Comparison of the natural history of ulcerative colitis in African Americans and non-Hispanic Caucasians: A historical cohort study, Inflammatory Bowel Diseases, vol.9, issue.4, 2011.
DOI : 10.1002/ibd.20298